IGF-1: The Growth-Hormone Marker That Isn't a Longevity Dial

IGF-1 has become a fashionable number in longevity circles — quoted in podcasts, tracked by biohackers, and often misunderstood as a "younger is higher" dial you'd want to crank up. The real picture is more interesting and more useful: IGF-1 is a precise clinical tool with a genuine paradox at its heart, where both too much and too little carry risk. This is a plain-language, current guide to what it measures, why it's central to growth-hormone medicine, and why it's not a wellness score to maximise. It's general education, not a diagnosis; your own results are interpreted by a doctor who knows your history.

What is IGF-1?

IGF-1 (insulin-like growth factor 1) is a hormone made mainly by your liver in response to growth hormone (GH), and it carries out most of GH's growth and repair effects around the body ¹. The reason it's measured instead of GH is practical: GH is released in pulses and swings wildly through the day with sleep, food and exercise, so a single GH blood draw is almost impossible to interpret. IGF-1 is far steadier, so it acts as a stable, readable proxy for how much growth-hormone activity is actually going on ¹.

Its real clinical jobs

IGF-1 earns its place in medicine through two specific questions:

• Too much GH — acromegaly. A GH-producing pituitary tumour drives IGF-1 up, causing the gradual bony and tissue overgrowth of acromegaly. IGF-1 is the primary biochemical test: a normal age-adjusted level effectively rules it out, and bringing IGF-1 back into the normal range is the goal of treatment ².
• Too little GH — growth-hormone deficiency. A low IGF-1 (below roughly the 2.5th percentile for age) supports the diagnosis, and GH replacement is dosed to bring IGF-1 into the age-appropriate range — not above it ¹.

There's a third, increasingly common reason it's ordered, which we'll come to: monitoring growth-hormone peptide therapy.

Why age is everything

Here's a detail people consistently miss. IGF-1 isn't a fixed "good number" — it falls by roughly 15% per decade through adult life, with the steepest decline between about 21 and 50 ³. A level that's perfectly healthy for a 25-year-old would be distinctly high for a 60-year-old. That's why a raw IGF-1 value is essentially uninterpretable without age context, and why labs and specialists prefer to express it as an age- and sex-adjusted score (a standard-deviation score, or SDS) rather than a bare figure ³. If you've ever compared an IGF-1 result against a single "normal range," this is why it can mislead.

The longevity paradox

This is what makes IGF-1 genuinely fascinating — and where the popular framing goes wrong. In animal studies, turning the GH/IGF-1 axis down reliably extends lifespan, and people with Laron syndrome (who make almost no functional IGF-1) are strikingly protected from cancer and diabetes ⁴. That seems to argue for "lower is better."

But the human data are U-shaped, not a straight line. Very low IGF-1 in older adults tracks with frailty, muscle loss and worse outcomes, while high IGF-1 carries its own risks. A large European cohort (EPIC-Heidelberg) found that, compared with the middle of the range, both the lowest and the highest groups had higher all-cause mortality — the lowest fifth notably so ⁵. The takeaway is a "Goldilocks" one: there's a healthy middle, and neither extreme is where you want to be.

The cancer association — in proportion

The high-end risk deserves a careful, honest word. Across large populations, higher IGF-1 is consistently linked to a modestly higher risk of breast, prostate and colorectal cancer — in UK Biobank, on the order of an 8–11% higher risk per step up in IGF-1 ⁶. Genetic (Mendelian randomisation) studies point most clearly to a causal role for colorectal cancer, while the prostate and breast signals are less consistent ⁶. Two things to hold together: the link is real and worth respecting, but the effect sizes are modest, and for breast and prostate it's more association than proof. It's a reason not to push IGF-1 high — not a reason to panic about a mid-range result.

Why this matters for peptide therapy

This is where IGF-1 becomes directly relevant to a lot of people who come asking about growth-hormone peptides — sermorelin, CJC-1295/ipamorelin, tesamorelin, MK-677. These work by nudging your own GH up, and IGF-1 is the safety dashboard for that. The sensible principle, drawn straight from the U-shape and the cancer data, is to keep IGF-1 within the age-adjusted range and not let it run high ⁶. "More is better" is precisely the wrong instinct here. Anyone on or considering this kind of therapy needs IGF-1 measured and tracked — not to chase a high number, but to make sure they stay in the safe middle.

What we see at the clinic

IGF-1 comes up most with two very different groups in Pattaya: people with symptoms that turn out to warrant a proper pituitary work-up, and — more often — health-engaged visitors who've read that a high IGF-1 means a more youthful body and want to drive it up with peptides. We spend a lot of time gently correcting that second idea. IGF-1 is a number to interpret against your age and to keep in a healthy band, not a longevity score to maximise — the human evidence simply doesn't support "higher is younger," and the upper end carries a cancer-association rationale we take seriously. Where it genuinely earns its place is as a diagnostic test when there's a clinical reason, and as the safety gauge for anyone on growth-hormone or peptide therapy. We don't diagnose pituitary disease or start that therapy from a single number — that's a doctor's job with the full picture.

Common questions

Does a higher IGF-1 mean I'm "younger" or healthier? No — that's the central misunderstanding. Human mortality risk is U-shaped, so both low and high IGF-1 are worse than the middle, and the high end carries a modest cancer association ⁵. It's a target range, not a dial to maximise.

Why is my IGF-1 "low" — is something wrong? Maybe nothing. IGF-1 falls about 15% per decade, so a value that looks low against a generic range may be entirely normal for your age once it's properly age-adjusted ³. That age adjustment is the first thing a doctor checks.

Should I take peptides to raise my IGF-1? Not as a goal in itself. If you're on growth-hormone or peptide therapy, IGF-1 is monitored to keep you within the age range — not pushed high — precisely because the upper end is where the cancer association sits ⁶. It's a safety check, not a score to beat.

Does high IGF-1 cause cancer? It's associated with a modestly higher risk of certain cancers, and the genetic evidence is strongest for colorectal; for breast and prostate it's less certain ⁶. Real enough to respect, modest enough not to over-read — and a reason to avoid driving IGF-1 up needlessly.

Is IGF-1 a good general anti-ageing test? On its own, no. It's a diagnostic and monitoring tool for specific GH conditions and therapies, not a validated standalone wellness or longevity screen ¹. Its meaning comes from context, not from a single high or low value.

Key takeaway

IGF-1 is the steady, readable proxy for growth-hormone activity — the primary test for acromegaly, a key test for GH deficiency, and the safety gauge for growth-hormone peptide therapy ¹. Read it against your age (ideally as an age- and sex-adjusted score), never as a raw number ³. And resist the longevity-hype framing: the human data are U-shaped, with risk at both ends — frailty when it's too low, a modest cancer association when it's too high ⁵. It's a number to keep in a healthy middle, not a dial to push — which is exactly why, if you're exploring peptides, measuring and tracking it matters as part of a sensible baseline.